

FOR IMMEDIATE RELEASE

February 8, 2007

Contact: Laura Strong

(608) 441-2950

LauraS@Quintbio.com

Quintessence Biosciences, Inc. Names Laura Strong, Ph.D. as President

MADISON, WISCONSIN – Quintessence Biosciences today announced the appointment of Laura Strong, Ph.D. to the position of the Company's President and Chief Operating Officer. Dr. Strong, a graduate in Chemistry from the University of Wisconsin-Madison and Board Member of the Wisconsin Biotechnology and Medical Device Association has served as the Company's Vice President since the year 2000. The appointment was recently made by the Company's Board of Directors and announced by Quintessence Board Chairman and CEO Ralph Kauten at the Annual Meeting of Shareholders.

"Dr. Strong brought a strong scientific background to Quintessence Biosciences and has quickly developed a broad range of business skills and expertise," said Mr. Kauten. "She has shown leadership which resulted in the Company making significant progress in selecting a lead cancer drug candidate and moving that candidate toward human clinical trials," Kauten continued. "In an environment that is fraught with intellectual property challenges and the rigors of FDA regulatory compliance, sound knowledge-based decision making and precise planning and execution is vital. Dr. Strong has shown the ability to establish a sound drug development plan and oversee its precise execution."

The Board's appointment follows the successful completion of drug screening activities that resulted in selection of QBI-139 as the Company's lead candidate for human clinical trials expected to begin in early 2008. QBI-139, based upon the Company's proprietary EVade™ Ribonuclease Technology has proven effective against non-small cell lung cancer, pancreatic cancer, ovarian cancer and prostate cancer.

Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of cancer therapies. The Company's vision is to improve the lives of cancer

patients by developing new drugs based on proprietary EVade™ Ribonuclease technologies. For more information, visit www.quintbio.com.

###